| Ident. | Authors (with country if any) | Title |
|---|
| 000108 |
A. Laux-Biehlmann [France] ; J. Mouheiche [France] ; J. Veriepe [France] ; Y. Goumon [France] | ENDOGENOUS MORPHINE AND ITS METABOLITES IN MAMMALS: HISTORY, SYNTHESIS, LOCALIZATION AND PERSPECTIVES |
| 000232 |
Sophie Schumm [France] ; Claude Sebban [France] ; Charles Cohen-Salmon [France] ; Jacques Callebert [France] ; Jean-Marie Launay [France] ; Jean-Louis Golmard [France] ; Lydie Boussicault [France] ; Isabelle Petropoulos [France] ; Audrey Hild [France] ; Estelle Rousselet [France] ; Annick Prigent [France] ; Bertrand Friguet [France] ; Jean Mariani [France] ; Etienne C. Hirsch [France] | Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine |
| 000B38 |
Frédéric Libert [France] ; Francois Coudore [France] ; Damien Richard [France] ; Franck Durif [France] ; Alain Eschalier [France] | Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine |
| 000C25 |
William J. Burke [États-Unis] ; SHU WEN LI [États-Unis] ; Hyung D. Chung [États-Unis] ; David A. Ruggiero [États-Unis] ; Bruce S. Kristal [États-Unis] ; Eugene M. Johnson [États-Unis] ; Patricia Lampe [États-Unis] ; Vijaya B. Kumar [États-Unis] ; Mark Franko [États-Unis] ; Evelyn A. Williams [États-Unis] ; Daniel S. Zahm [États-Unis] | Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases |
| 000E97 |
Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Francois Huguet [France] ; Bernard Fauconneau [France] | Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+ |
| 000F45 |
A. D. Smith [États-Unis] ; M. Amalric [France] ; G. F. Koob [États-Unis] ; M. J. Zigmond [États-Unis] | Effect of bilateral 6-hydroxydopamine lesions of the medial forebrain bundle on reaction time |
| 001175 |
A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
| 001179 |
Saliha Moussaoui [France] ; Maria-Carmen Obinu [France] ; Nadine Daniel [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Assunta Imperato [France] | The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease |
| 001237 |
A. Nicotra [Italie] ; S. H. Parvez [France] | Cell death induced by MPTP, a substrate for monoamine oxidase B |
| 001316 |
S. Bourgoin [France] ; S. Rostaing-Rigattieri [France] ; J.-P. Nguyen [France] ; E. Berberich [France] ; P. Duvaldestin [France] ; C.-M. Fattaccini [France] ; M. Hamon [France] ; F. Cesselin [France] | Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation |
| 001634 |
M. Strittmatter [Allemagne] ; G. F. Hamann [Allemagne] ; D. Strubel [France] ; H. Cramer ; K. Schimrigk [Allemagne] | Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease : effect of L-Dopa |
| 001790 |
J. Dow [France] ; F. Piriou ; E. Wolf [France] ; B. D. Dulery [France] ; K. D. Haegele | Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans |
